← Back
NeuroTrials.ai
Neurology Clinical Trial Database

BILATERAL tDCS-DYSPHAGIA

Intensive Rehabilitation With Adjunctive Bilateral Anodal tDCS in Post-Stroke Dysphagia: A Multicenter Randomized Controlled Trial

Year of Publication: 2026

Authors: Cosentino G, Bocci T, Cecchi F, ..., Alfonsi E

Journal: European Journal of Neurology

Citation: Eur J Neurol 2026;33:e70686

Link: https://doi.org/10.1111/ene.70686

Bottom Line

Six weeks of intensive speech-language therapy produced significant, clinically meaningful improvements in swallowing across DOSS, PAS, MASA and SWAL-QoL in both arms, with no overall superiority of bilateral anodal tDCS over sham; exploratory analyses suggest a possible additional benefit in infratentorial strokes.

Major Points

  • Multicenter (5 Italian centers), randomized, double-blind, sham-controlled trial (NCT07152899) enrolling 48 patients (46 completed) with supra- or infratentorial ischemic post-stroke oropharyngeal dysphagia (72 h - 6 months post-onset).
  • Bilateral anodal tDCS (1.5 mA x 20 min, 5 days/week for 2 weeks; two 5x7 cm anodes over orofacial swallowing cortices, contralateral 10x10 cm cathodes) was combined with 6 weeks of intensive 40-min/day SLT.
  • Primary DOSS outcome improved significantly within both arms at 2 and 6 weeks (all p<0.001), with no significant between-group difference in delta DOSS.
  • Secondary outcomes (PAS, MASA, SWAL-QoL) also improved in both arms without between-group differences overall.
  • Exploratory: in infratentorial strokes, active tDCS produced significantly greater MASA gains than sham at 2 weeks (p=0.04); higher baseline severity (lower MASA, higher PAS, higher NIHSS) predicted larger gains.
  • Stimulation was well tolerated with no adverse events; qualitative blinding was maintained.
  • Authors interpret findings as evidence that intensive prolonged SLT is the main driver of recovery, with tDCS possibly adding benefit only in selected lesion subgroups (infratentorial).

Design

Study Type: Randomized Controlled Trial

Randomization: 1

Blinding: Double-blind (patients and outcome assessors blinded; centralized 1:1 randomization)

Enrollment Period: June 2021 - May 2025

Follow-up Duration: 6 weeks (assessments at baseline, 2 weeks/end of stimulation, 6 weeks/end of SLT)

Centers: 5

Countries: Italy

Sample Size: 48

Analysis: Non-parametric within-group (Friedman + Wilcoxon signed-rank with Bonferroni) and between-group (Mann-Whitney U on delta scores); powered for within-group changes (n=38 gave 90% power)


Inclusion Criteria

  • Adults aged >=18 years
  • First-ever or recurrent ischemic stroke confirmed on neuroimaging (supratentorial or infratentorial)
  • Oropharyngeal dysphagia confirmed by fiberoptic endoscopic evaluation of swallowing (FEES) with DOSS <=6
  • Time from stroke onset between 72 hours and 6 months
  • Able to participate in intensive speech-language therapy
  • Written informed consent obtained

Exclusion Criteria

  • Pre-existing dysphagia unrelated to stroke
  • Severe cognitive impairment interfering with therapy participation
  • Progressive neurological or oncological diseases
  • Standard contraindications to tDCS (metallic cranial implants, pacemakers, other implanted electronic devices)
  • History of seizures or active epilepsy
  • Dermatological conditions at the electrode sites

Baseline Characteristics

CharacteristicActiveControlOverall cohort
N24 (24 completed)24 (22 completed; 2 discontinued for logistic reasons)
Mean Age (years)62.7 +/- 1467.9 +/- 12.6
Sex - Male16/24 (67%)16/22 (approx 73%)
Sex - Female8/24 (33%)6/22 (approx 27%)
Days from stroke onset37.2 +/- 44.860.9 +/- 50.2
NIHSS8.3 +/- 4.69.7 +/- 5.59 +/- 5
DOSS (baseline)2.9 +/- 1.83.1 +/- 1.5
PAS (baseline)3.4 +/- 2.33.8 +/- 2.4
MASA (baseline)157.6 +/- 23.7154.1 +/- 28.1
SWAL-QoL (baseline)147.5 +/- 22.1141.4 +/- 22.8
Total46 completed (14 female, 32 male)
Age (years)65.2 +/- 13.4
Days from onset57.3 +/- 77.8
DOSS3 +/- 1.6
PAS3.6 +/- 2.3
MASA156 +/- 25.7
SWAL-QoL144.1 +/- 22.3
NoteBaseline clinical and demographic variables did not differ significantly between active and sham groups. Infratentorial strokes had more severe baseline dysphagia (lower DOSS, higher PAS) and males had greater baseline impairment than females.

Arms

FieldBilateral anodal tDCS + intensive SLTControl
InterventionBilateral anodal tDCS 1.5 mA x 20 min/session, 5 days/week for 2 weeks (10 sessions). Two 5x7 cm anodes over orofacial swallowing cortices (3.5 cm lateral and 1 cm anterior to vertex, bilaterally); two 10x10 cm cathodes placed contralaterally. Delivered concurrently with 40-min daily intensive SLT for 6 weeks (individualized swallowing and non-swallowing exercises, compensatory/postural strategies, progressive oropharyngeal strengthening).Sham tDCS using identical electrode placement; current delivered only for 30 s at the beginning and again for 30 s at the end of each session to mimic transient cutaneous sensation without sustained cortical effects. Same intensive 40-min daily SLT for 6 weeks.
Duration2 weeks of stimulation + 6 weeks total SLT2 weeks of sham stimulation + 6 weeks total SLT

Outcomes

OutcomeTypeControlInterventionHR / OR / RRP-value
Improvement in swallowing function assessed by the Dysphagia Outcome and Severity Scale (DOSS) at 2 weeks (end of stimulation) and 6 weeks (end of intensive SLT).PrimaryWithin-group p<0.001 in both arms; between-group NS
Penetration-Aspiration Scale (PAS)SecondaryControl (Sham) - Baseline / 2 wk / 6 wk: 3.8 +/- 2.4 / 3.3 +/- 2.3 / 2.9 +/- 2.3 · Intervention (Anodal) - Baseline / 2 wk / 6 wk: 3.4 +/- 2.3 / 2.8 +/- 2.5 / 2.6 +/- 2.5 · Within-group P: Anodal Friedman p=0.0006 (baseline vs 6 wk p=0.01); Sham Friedman p=0.003 (baseline vs 6 wk p=0.01) · Between-group P: NS overall
Mann Assessment of Swallowing Ability (MASA)SecondaryControl (Sham) - Baseline / 2 wk / 6 wk: 154 +/- 28.1 / 164 +/- 30.6 / 169 +/- 31.6 · Intervention (Anodal) - Baseline / 2 wk / 6 wk: 158 +/- 23.7 / 171 +/- 21.9 / 176 +/- 22.5 · Within-group P: Both arms Friedman p<=0.00001 (all pairwise Bonferroni-significant) · Between-group P: NS overall; infratentorial subgroup: significantly greater gain with active at 2 weeks (p=0.04)
Swallowing Quality of Life (SWAL-QoL) at 6 weeksSecondaryControl (Sham) - Baseline / 6 wk: 148 +/- 16.8 / 183.2 +/- 13.5 (p=0.0006) · Intervention (Anodal) - Baseline / 6 wk: 142 +/- 15.6 / 176 +/- 18.6 (p=0.02) · Between-group P: NS overall
Infratentorial subgroup - DOSS (active vs sham)SecondaryTrend at 2 weeks (p=0.07); NS at 6 weeks (p=0.16)
Infratentorial subgroup - PAS (active vs sham)SecondaryNS at both time points (p=0.5 and p=1)
Timing of treatment initiation (early <=4 weeks vs late >4 weeks)SecondaryNo significant differences in swallowing improvement between early and late initiation, either overall or within active/sham arms
Correlations with baseline severity (Spearman)SecondaryGreater baseline dysphagia severity predicted larger gains: lower baseline MASA correlated with greater MASA gains (delta 2 wk r=-0.54 p=0.002; delta 6 wk r=-0.52 p=0.004) and greater PAS gains (delta 2 wk r=-0.54 p=0.002); higher baseline PAS correlated with larger DOSS gains at 6 wk (r=-0.56 p=0.002), PAS gains (delta 2 wk r=-0.51 p=0.004), MASA gains (delta 6 wk r=-0.41 p=0.03), and SWAL-QoL gains (delta 6 wk r=-0.46 p=0.01). Higher baseline NIHSS correlated with greater PAS improvement at 2 wk (r=0.39 p=0.007).
OverallAdverseNo adverse events or side effects reported in any patient in either arm
Serious Adverse EventsAdverseNone reported
DiscontinuationsAdverse0 in active tDCS arm; 2 in sham arm (both for logistic reasons, not tolerability)
TolerabilityAdverseBoth groups reported comparable transient sensory experiences (tingling / current sensation at start and end of stimulation); no participant could reliably distinguish active from sham, supporting blinding integrity

Subgroup Analysis

Prespecified exploratory subgroups: lesion location (supratentorial vs infratentorial), treatment timing (early <=4 wk vs late >4 wk post-onset), and sex. Infratentorial subgroup showed significantly greater MASA gains with active tDCS at 2 weeks (p=0.04) and a non-significant trend for DOSS at 2 weeks (p=0.07); no supratentorial differences. Males showed larger gains in MASA and SWAL-QoL than females, likely reflecting greater baseline severity. Timing did not modify outcomes.


Criticisms

  • Small sample size (46 completed) limits power to detect modest between-group differences and precludes formal stratified subgroup inference, particularly for the infratentorial signal.
  • Broad recruitment window (72 h - 6 months post-stroke) introduces heterogeneity in spontaneous recovery trajectories that may mask a true tDCS effect.
  • Very intensive SLT program (40 min/day, 5 days/week, 6 weeks) may have produced a ceiling effect leaving little margin for additional neuromodulatory benefit.
  • Inclusion of patients with only mild-to-moderate dysphagia further reduces the detectable margin of improvement.
  • Bilateral montage using standardized scalp coordinates may generate diffuse cortical fields and lacks individualized neuronavigation or TMS-guided targeting.
  • Delayed ClinicalTrials.gov registration (NCT07152899) due to COVID-19 pandemic constraints (registered retrospectively).
  • No untreated control arm (ethically precluded), so absolute contribution of spontaneous recovery vs SLT cannot be isolated.
  • Blinding success was assessed only qualitatively, not with a formal instrument.
  • Single-country (Italian) recruitment limits generalizability; only ischemic strokes included.
  • Exploratory subgroup analyses (including the positive infratentorial MASA finding) are hypothesis-generating and not adjusted for multiple comparisons across subgroups.

Funding

Italian Ministry of Health (Ricerca Corrente 2025-2027); Bando Ricerca Finalizzata 2019 (project GR-2019-12369182). Open access publishing via Universita di Pavia through Wiley-CRUI-CARE agreement. Conflict of interest: Shaheen Hamdy is Chief Scientific Officer at Phagenesis Ltd. and holds stocks/shares; all other authors declare no competing interests.

Based on: BILATERAL tDCS-DYSPHAGIA (European Journal of Neurology, 2026)

Authors: Cosentino G, Bocci T, Cecchi F, ..., Alfonsi E

Citation: Eur J Neurol 2026;33:e70686

Content summarized and formatted by NeuroTrials.ai.